UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 2,604	$ 3,041
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	211	200
Amortization	462	509
Provision for losses on/(recovery of) accounts receivable	(5)	(9)
Amortization of Right-of-Use Assets	15	12
Deferred income taxes	(157)	(209)
Stock-based compensation expense	120	82
Accounts receivable and other receivables	(130)	12
Inventories	(830)	275
Prepaid expenses and other current assets	(92)	(26)
Accounts payable	284	217
Accrued expenses	627	360
Total adjustments	505	1,423
Net cash provided by operating activities	3,109	4,464
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(130)	(184)
Net cash provided by/(used in) investing activities	(130)	(184)
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock purchased and retired	(128)	(3,221)
Payment of dividends	(989)	(1,017)
Net cash used in financing activities	(1,117)	(4,238)
Effect of exchange rate changes on cash	(212)	307
Net increase in cash and cash equivalents	1,650	349
Cash at beginning of period	85,756	82,976
Cash at end of period	87,406	83,325
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for income taxes	30	46
Cash paid during the period for interest	$ 0	$ 0